177Lu-PSMA Treatment Monitoring Through Serial Fast Whole-Body Tomoscintigraphies Recorded With a Latest-Generation CZT-Camera.
Fiche publication
Date publication
octobre 2023
Journal
Clinical nuclear medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MARIE Pierre-Yves, Pr OLIVIER Pierre, Dr CLAUDIN Marine
Tous les auteurs :
Boursier C, Olivier P, Claudin M, Marie PY, Imbert L
Lien Pubmed
Résumé
The tomoscintigraphy monitoring of 177Lu-prostate-specific membrane antigen (PSMA) treatment may be helpful for quality control and predicting therapeutic response. Furthermore, the drawbacks of relatively low image quality and extended recording times can be overcome by new CZT-cameras providing fast, high-quality, whole-body recordings. Although still requiring further larger-scale confirmation, the current case report demonstrates that these CZT-cameras have the potential to provide straightforward and comprehensive 177Lu-PSMA treatment monitoring, that is, <20-minute whole-body tomoscintigraphy recording, tumor activities concordant with those from 68Ga-PSMA PET, and no requirement for any additional tracer injection.
Mots clés
Male, Humans, Lutetium, therapeutic use, Quality Control, Radioisotopes
Référence
Clin Nucl Med. 2023 10 1;48(10):e491-e493